RSCM
SPRO icon

Rock Springs Capital Management’s Spero Therapeutics SPRO Stock Holding History

Rock Springs Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-57,373
Closed -$69.4K – 113
2023
Q3 		$69.4K Sell
57,373
-612,160
-91% -$848K ﹤0.01% 118
2023
Q2 		$971K Hold
669,533
– – 0.02% 116
2023
Q1 		$971K Hold
669,533
– – 0.02% 113
2022
Q4 		$1.16M Sell
669,533
-101,177
-13% -$189K 0.03% 110
2022
Q3 		$1.54M Hold
770,710
– – 0.04% 115
2022
Q2 		$571K Sell
770,710
-220,203
-22% -$640K 0.02% 129
2022
Q1 		$8.62M Buy
990,913
+45,600
+5% +$467K 0.22% 87
2021
Q4 		$15.1M Buy
945,313
+3,770
+0.4% +$59.9K 0.35% 75
2021
Q3 		$17.3M Sell
941,543
-24,385
-3% -$391K 0.36% 79
2021
Q2 		$13.5M Hold
965,928
– – 0.27% 99
2021
Q1 		$14.2M Sell
965,928
-269,072
-22% -$4.74M 0.31% 89
2020
Q4 		$23.9M Sell
1,235,000
-1,256
-0.1% -$19.6K 0.51% 70
2020
Q3 		$13.8M Buy
1,236,256
+621,079
+101% +$7.35M 0.35% 84
2020
Q2 		$8.32M Buy
615,177
+10,177
+2% +$114K 0.23% 111
2020
Q1 		$4.89M Buy
605,000
+80,000
+15% +$705K 0.2% 99
2019
Q4 		$5.05M Hold
525,000
– – 0.16% 108
2019
Q3 		$5.57M Hold
525,000
– – 0.22% 98
2019
Q2 		$6.04M Hold
525,000
– – 0.22% 93
2019
Q1 		$6.72M Hold
525,000
– – 0.26% 97
2018
Q4 		$3.23M Hold
525,000
– – 0.15% 114
2018
Q3 		$5.52M Hold
525,000
– – 0.2% 113
2018
Q2 		$7.7M Hold
525,000
– – 0.3% 98
2018
Q1 		$7.48M Hold
525,000
– – 0.32% 95
2017
Q4 		$6.17M Buy
+525,000
New +$6.44M 0.28% 99

Other funds holding SPRO

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rock Springs Capital Management's SPRO Position: Q4 2023 in Review

Rock Springs Capital Management sold out of Spero Therapeutics (SPRO) in Q4 2023, closing a stake of 57,373 shares — an estimated $69.4K sold.

Rock Springs Capital Management first reported a position in SPRO in Q4 2017 and held it in 24 quarters. The position peaked at $23.9M in Q4 2020. 50 funds tracked by Wall St. Rank hold SPRO as of Q4 2023.

  • Rock Springs Capital Management reported no remaining Spero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Rock Springs Capital Management sold 57,373 Spero Therapeutics shares in Q4 2023, an estimated $69.4K.
  • Rock Springs Capital Management first reported a position in Spero Therapeutics in Q4 2017 and held it in 24 quarters.
  • Rock Springs Capital Management's Spero Therapeutics position peaked at $23.9M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2023.

Based on Rock Springs Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.